Cover Image

Novel drug therapies for atrial fibrillation

Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers. Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Wiedmann, Felix Tobias (Author) , Schmidt, Constanze (Author)
Format: Article (Journal)
Language:English
Published: May 2024
In: Nature reviews. Cardiology
Year: 2024, Volume: 21, Issue: 5, Pages: 275-276
ISSN:1759-5010
DOI:10.1038/s41569-024-01004-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41569-024-01004-2
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41569-024-01004-2
Get full text
Author Notes:Felix Wiedmann, Constanze Schmidt
Description
Summary:Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers. Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with new-onset atrial fibrillation. As a result, a paradigm shift towards rhythm control over rate control therapy is emerging, increasing the clinical need for effective and safe antiarrhythmic drugs.
Item Description:Online veröffentlicht: 28. Februar 2024
Gesehen am 28.11.2024
Physical Description:Online Resource
ISSN:1759-5010
DOI:10.1038/s41569-024-01004-2

Similar Items